Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical imaging specialist EMVision (EMV) has released what it calls “highly promising” results from its pilot stroke clinical trial
  • The trial is designed to test EMVision’s imaging tech against conventional scanning methods — in this case, MRI and CT scans
  • The first results from the trial show that in two patients, the EMV tech was able to accurately locate abnormal brain tissue
  • EMVision is creating a portable imaging device designed to be quicker and cheaper than the conventional scanning methods
  • Shares in the company are trading over nine per cent higher after today’s results, currently worth 82 cents each

Medical imaging specialist EMVision (EMV) has released the first set of “promising” images from its ongoing stroke clinical trial.

The company is creating a portable medical imaging device designed to create 3D images of biological tissue faster and cheaper than conventional imaging methods.

The company’s current pilot clinical trial is testing the EMVision tech against conventional “ground truth” brain scans — in this case, MRI and CT scans.

Essentially, the EMVision trial is designed to monitor the brains of stroke patients to detect and localise abnormal brain tissue.

Comparing the pair

The EMV scans, when compared with prior MRI and CT scans, have shown some encouraging results.

Sourced: EMVision

The above image, produced by EMV, contrasts the EMV scan against the ground truth MRI and CT scan in two different patients. When compared with the conventional scans, the EMV tech was in both cases able to accurately localise abnormal brain tissue which is distinctive from the surrounding brain tissue.

EMVision clinical advisor and neurologist Professor Michael O’Sullivan said although preliminary, these results are “highly promising”.

“In both cases, the EMVision scans were clearly positive and provided a good guide to the extent of brain tissue damaged or under threat,” Michael said.

High praise

The Co-chairs of the Australian Stroke Alliance and former presidents of the World Stroke Organization, Professors Stephen Davis and Geoffrey Donnan, shared similar sentiments to Michael.

“These early images are clinically promising, clearly showing the effects of ischemic stroke in the same region as the gold standard imaging methods,” Stephen said.

Speaking to the commercial viability of the tech, Geoffrey went as far as to say: “the lightweight portability of the device makes it a potential candidate for emergency stroke imaging in the pre-hospital setting.”

The aim of the trial, which kicked off in late January 2020, is to improve the understanding of the effect strokes have on the brain. EMVision claims its system is entirely unique.

Investors seem pleased with today’s early test results. Despite a tough day on the ASX, EMV shares are trading 9.33 per cent higher in early afternoon trade, currently worth 82 cents each.

EMV by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.